MedPath

Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update

Completed
Conditions
Dengue Virus Infection
Interventions
Other: No intervention
Registration Number
NCT04170140
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Brief Summary

The primary objective of the study is to evaluate the effectiveness of additional risk minimization measures material by assessing the knowledge and understanding of healthcare professionals regarding the key safety messages provided in the material.

The secondary objective of the study is to evaluate if healthcare professionals know Dengvaxia product information, namely, age indication and contraindications.

Detailed Description

The study is a cross-sectional Survey. Study data are collected through a questionnaire.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Prescribers of DengvaxiaNo interventionHealthcare professionals who are current or past prescribers of Dengvaxia
Primary Outcome Measures
NameTimeMethod
Healthcare professionals' knowledge and understanding of key safety messages provided in risk minimization measures materialsDay 0

Knowledge and understanding of key safety messages are assessed through a questionnaire

Secondary Outcome Measures
NameTimeMethod
Healthcare professionals' knowledge of Dengvaxia product informationDay 0

Knowledge of Dengvaxia product information (age indication and contraindications) is assessed through a questionnaire

Trial Locations

Locations (1)

Real World Evidence Solutions IQVIA

🇫🇷

La Defense, France

© Copyright 2025. All Rights Reserved by MedPath